Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE EVICT CORONA-ALI
NCT04344184Phase 2Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Dec 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ascorbic acid in coronavirus disease 2019 (COVID-19) and acute lung injury (ALI) (2 arms), sponsored by Virginia Commonwealth University. Primary endpoint: Change in COVID Disease Status at 90 days. Started Dec 2020; status: completed.
02
Drugs
ascorbic acid
03
Conditions
coronavirus disease 2019 (COVID-19)acute lung injury (ALI)
Beyond the preview
Go deeper on NCT04344184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04344184.